Chronic Pain Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Neuropathic Pain, Analgesic Infusion, Ablation), By Product Type (Drugs, Devices), By Distribution Channel (Hospital & Clinics, Ambulatory Centers, Others), By Region and Competition, 2020-2030F

Market Overview

Global Chronic Pain Treatment Market was valued at USD 84.23 Billion in 2024 and is expected to reach USD 132.08 Billion in the forecast period with a CAGR of 7.76% through 2030. The global chronic pain treatment market is experiencing substantial expansion, driven by an increasing number of individuals suffering from long-term pain conditions such as arthritis, neuropathy, fibromyalgia, and lower back pain. The rising aging population contributes significantly to market growth, as elderly individuals are more prone to chronic pain due to degenerative diseases and musculoskeletal disorders. Advances in medical research have led to the development of more effective pain management solutions, ranging from pharmaceutical interventions like non-opioid analgesics and biologics to non-pharmacological treatments such as neurostimulation and regenerative medicine. Increasing patient awareness regarding available treatment options and the integration of personalized medicine in pain management are enhancing the adoption of innovative therapies. Growing healthcare expenditure and improved reimbursement policies in various countries further support market expansion, allowing patients greater access to advanced chronic pain treatments.

The demand for safer and more effective pain management strategies is shaping key market trends, with a notable shift toward non-opioid therapies due to concerns over opioid addiction and dependency. The emergence of neuromodulation technologies, including spinal cord stimulation and transcutaneous electrical nerve stimulation (TENS), is revolutionizing chronic pain treatment by offering targeted and minimally invasive solutions. Regenerative medicine, including stem cell therapy and platelet-rich plasma (PRP) injections, is gaining traction as a promising alternative for long-term pain relief and tissue repair. Digital health solutions, such as mobile applications and wearable devices, are improving pain management by enabling remote monitoring, patient engagement, and data-driven treatment plans. The increasing focus on multidisciplinary pain management approaches, which combine pharmacological, interventional, and psychological therapies, is contributing to better patient outcomes and driving market growth.

Despite the market’s rapid expansion, several challenges hinder its full potential. The high cost of advanced pain treatments and limited reimbursement for emerging therapies restrict access for many patients, particularly in lower-income populations. Regulatory hurdles surrounding novel pain management solutions, including strict approval requirements for new drugs and medical devices, can delay market entry and innovation. Concerns over the long-term efficacy and safety of newer treatment modalities, such as regenerative therapies and neuromodulation, create uncertainty among healthcare providers and patients. The shortage of pain management specialists and the lack of standardized treatment protocols in some regions lead to inconsistencies in care delivery. Addressing these challenges through continued investment in research, improved regulatory frameworks, and better patient education will be crucial in sustaining the growth and evolution of the chronic pain treatment market in the coming years.

Key Market Drivers

Increasing Aging Population

The increasing aging population is a pivotal driver for the Global Chronic Pain Treatment Market, impacting the healthcare industry in several profound ways. With age comes an increased susceptibility to chronic pain conditions such as osteoarthritis, rheumatoid arthritis, neuropathy, and musculoskeletal disorders. In 2022, the age-adjusted prevalence of diagnosed arthritis in U.S. adults was 18.9%, with the percentage rising significantly with age from 3.6% in adults aged 18–34 to 53.9% in those aged 75 and older. This heightened prevalence among the elderly directly fuels the demand for effective pain management solutions.

Advances in healthcare have resulted in extended life expectancy worldwide. For instance, in 2023, life expectancy at birth for the U.S. population increased to 78.4 years, up from 77.5 years in 2022. While this is a remarkable achievement, it also means that a significant portion of the population is living longer, thereby increasing the likelihood of experiencing chronic pain as they age. Elderly individuals commonly suffer from multiple chronic health conditions simultaneously, which can exacerbate pain symptoms and necessitate more complex and comprehensive pain management strategies.

The aging population significantly expands the potential market size for chronic pain treatment products and services. To cater to the unique needs of older individuals, businesses are incentivized to innovate, developing age-specific pain medications, medical devices, and therapies that are safer and more effective for the elderly population. Effective marketing strategies should address the concerns and preferences of older consumers, emphasizing the safety and efficacy of products and services for seniors. Companies in the chronic pain treatment sector may explore partnerships with healthcare providers and geriatric specialists to ensure a holistic approach to pain management for aging patients. Furthermore, the aging population presents opportunities for research and clinical trials focused on chronic pain treatment, potentially leading to breakthroughs in understanding age-related pain mechanisms and the development of more targeted interventions.

Technological Advancements

Technological advancements are a crucial market driver for the Global Chronic Pain Treatment Market, reshaping the landscape of pain management and treatment options. Modern medical imaging technologies, such as MRI, CT scans, and PET scans, have revolutionized the diagnosis of chronic pain conditions. These imaging techniques enable healthcare providers to pinpoint the exact source of pain, leading to more accurate and personalized treatment plans. The pharmaceutical industry has seen remarkable advancements in the development of pain-relief medications. This includes the creation of novel analgesics with improved safety profiles and reduced side effects, offering patients better pain management options.

Technological advancements in genomics and personalized medicine have paved the way for precision medicine in chronic pain treatment. Genetic profiling allows for tailored treatments that are more effective and have fewer adverse effects. The introduction of innovative medical devices, such as neurostimulation implants and pain pumps, has transformed the way chronic pain is managed. These devices offer targeted relief and improved quality of life for patients. Telemedicine platforms and remote monitoring technologies enable patients to receive ongoing care and consultations without the need for frequent in-person visits. This convenience is particularly valuable for elderly or immobile chronic pain patients. Mobile applications designed for pain management have gained popularity. These apps offer patients tools for tracking their pain, monitoring medication schedules, and accessing educational resources. VR and AR technologies are increasingly used in pain distraction therapy. Patients can immerse themselves in virtual environments, diverting their attention from pain and reducing discomfort during medical procedures or rehabilitation.

Increased Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is a significant driver for the Global Chronic Pain Treatment Market, with far-reaching implications for healthcare systems and pain management strategies. According to the World Health Organization (WHO), non-communicable diseases (NCDs) such as cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes account for over 70% of global deaths annually. Many of these conditions are associated with chronic pain, necessitating effective long-term pain management solutions.

The aging global population further exacerbates the prevalence of chronic diseases. The United Nations Department of Economic and Social Affairs reports that the number of persons aged 65 years or over is projected to double from 761 million in 2021 to 1.6 billion in 2050. This demographic shift is significant, as older individuals are more susceptible to conditions like osteoarthritis and neuropathy, which often require ongoing pain management.

Modern lifestyles characterized by physical inactivity, unhealthy diets, and stress contribute to the rise in chronic diseases. The WHO indicates that insufficient physical activity is a leading risk factor for NCDs, with approximately 1 in 4 adults not meeting recommended activity levels. These lifestyle-related conditions often involve chronic pain, prompting individuals to seek effective treatment options.

Governments and healthcare organizations are prioritizing the prevention and management of chronic diseases due to their substantial impact on public health and economies. The WHO emphasizes that NCDs are not only a health issue but also a significant economic concern, as they lead to productivity losses and increased healthcare costs. This focus drives investment in healthcare infrastructure and the development of comprehensive pain treatment strategies.

Patients with chronic diseases often experience multiple health issues simultaneously, known as comorbidities, which can exacerbate pain symptoms and complicate treatment plans. The Centers for Disease Control and Prevention (CDC) notes that 6 in 10 adults in the U.S. have a chronic disease, and 4 in 10 have two or more, highlighting the need for integrated and effective pain management solutions.

These factors collectively underscore the growing demand for chronic pain treatments, driving innovation and expansion in the Global Chronic Pain Treatment Market.

Rising Healthcare Expenditure

Rising healthcare expenditure is a critical market driver for the Global Chronic Pain Treatment Market, significantly influencing the dynamics of this sector. The increase in healthcare spending has far-reaching implications, both for patients seeking pain management solutions and for businesses operating within the chronic pain treatment industry. As healthcare expenditure rises, individuals have greater access to healthcare services. This accessibility means that more patients can seek treatment for chronic pain, contributing to a higher demand for chronic pain management solutions. The growth in healthcare spending often goes hand in hand with investments in advanced medical technologies. These technologies can lead to the development of innovative pain management devices, medications, and therapies.

Greater healthcare expenditure often results in the expansion and improvement of healthcare infrastructure. This includes the construction of state-of-the-art hospitals, clinics, and rehabilitation centers, all of which require comprehensive pain management solutions. Increased funding in healthcare enables more substantial investments in research and development (R&D). This can lead to breakthroughs in understanding chronic pain mechanisms and the creation of more effective treatments. With rising healthcare expenditure, there is improved accessibility to a wide range of medications. This accessibility ensures that patients have access to pain-relief drugs, both over the counter and prescription, which play a pivotal role in chronic pain management.

Download Free Sample Report

Key Market Challenges

Opioid Crisis and Regulatory Scrutiny

The opioid crisis, characterized by the misuse and addiction to prescription opioid pain relievers, has led to heightened regulatory scrutiny on the use of opioids in chronic pain management. In response to the crisis, regulators have imposed stricter guidelines on opioid prescribing, distribution, and monitoring.

Stricter regulations have made it more challenging for patients to access opioid-based pain medications, even when medically necessary, leading to concerns about undertreated pain. Healthcare providers and pharmaceutical companies face increased legal liability related to opioid prescriptions, which can result in cautious prescribing practices and a reluctance to develop new opioid-based pain medications.

The crisis has shifted the focus toward non-opioid alternatives for chronic pain management. While this is a positive development, it poses a challenge for businesses in the opioid-based pain medication market.

Limited Reimbursement for Pain Management Services

Many healthcare systems and insurance providers have limitations on reimbursement for pain management services, including non-pharmacological therapies, physical therapy, and psychological interventions. Patients may face financial barriers to accessing comprehensive pain management services due to limited insurance coverage or high out-of-pocket expenses, deterring them from seeking necessary treatments.

Healthcare providers may have limited financial incentives to offer comprehensive pain management services, as reimbursement rates may not adequately cover the costs of these treatments. Effective non-pharmacological pain management options, such as physical therapy and cognitive-behavioral therapy, may be underutilized due to limited reimbursement, despite their potential to improve patient outcomes.

Key Market Trends

Rise in Non-Opioid Pain Management

Trend: There is a growing shift away from opioid-based pain management towards non-opioid alternatives. This trend is driven by concerns over the opioid crisis, regulatory restrictions on opioid prescriptions, and the desire to reduce the risk of addiction and overdose.

Opioid medications carry a risk of addiction and overdose, making non-opioid alternatives more attractive for patients and healthcare providers concerned about patient safety. Stricter regulations on opioid prescribing and dispensing have pushed healthcare providers to explore non-opioid treatments to comply with these guidelines.

Patients are increasingly seeking non-opioid options due to the fear of opioid-related side effects and addiction, creating a demand for alternative pain management solutions.

Personalized Medicine and Targeted Therapies

Advancements in genomics and personalized medicine are leading to the development of targeted pain management therapies. These therapies aim to provide individualized treatment plans based on a patient's genetic makeup, pain profile, and response to specific medications.

Personalized pain management allows for treatments that are tailored to a patient's unique physiology, increasing the likelihood of a positive response and pain relief. Targeted therapies can minimize the risk of adverse effects by matching patients with medications that are most likely to work for them.

Advances in diagnostic tools and genetic testing enable healthcare providers to identify genetic factors that influence a patient's pain experience, guiding treatment decisions.

Telemedicine and Digital Health Solutions

Telemedicine and digital health solutions have gained prominence in chronic pain management. These technologies allow for remote consultations, monitoring, and the delivery of pain management interventions through digital platforms.

Telemedicine overcomes geographical barriers, enabling patients in remote or underserved areas to access pain management services and consultations with specialists. Patients appreciate the convenience of virtual appointments and digital pain management tools, which can enhance treatment adherence.

Digital health solutions collect real-time data on patients' pain levels and treatment responses, facilitating more informed decisions and adjustments to pain management plans.

Segmental Insights

Product Type Insight

Based on the category of Product Type, the Drugs emerged as the dominant player in the global market for Chronic Pain Treatment in 2024. The drug segment offers a diverse range of options for chronic pain management. These options include non-opioid analgesics, opioids, adjuvant medications, and novel pharmaceuticals specifically designed for pain relief. This diversity allows healthcare providers to tailor treatment plans to individual patient needs. Drugs have long been the primary mode of treatment for chronic pain, resulting in established prescription and usage patterns within the medical community. Physicians are familiar with prescribing medications for pain management, and patients are accustomed to taking them.

The pharmaceutical industry invests heavily in research and development to discover and develop new pain medications. This commitment to innovation has led to the creation of advanced drugs, including opioids, non-opioid analgesics, and targeted therapies for specific pain conditions. Many patients prefer drug-based pain management due to its ease of use and familiarity. Oral medications, patches, and injectables are convenient for patients and often result in higher treatment compliance. The pharmaceutical industry operates within a well-defined regulatory framework that governs drug development, approval, and marketing. Pharmaceutical companies invest in rigorous clinical trials and adhere to regulatory standards to bring their pain medications to market.

Distribution Channel Insights

Based on the Distribution Channel, Hospital & Clinics emerged as the dominant segment in the Global Chronic Pain Treatment Market in 2024. Hospitals and clinics are staffed by healthcare professionals with specialized training in pain management. Pain specialists, anesthesiologists, neurologists, and physical therapists are commonly found in these settings. Their expertise allows for precise diagnosis and tailored treatment plans. Hospitals and clinics offer comprehensive diagnostic services, including advanced imaging (e.g., MRI, CT scans), nerve conduction studies, and electrodiagnostic testing. Accurate diagnosis is crucial for effective chronic pain management.

Hospitals and clinics are equipped with a wide range of treatment facilities, including operating rooms, procedure suites, infusion centers, and rehabilitation units. This infrastructure supports various treatment modalities, from medication management to surgical interventions. Hospitals and clinics provide a continuum of care, which means that patients can receive multiple services in one location. This convenience is particularly valuable for individuals with chronic pain who may require a combination of treatments, such as medication, physical therapy, and interventional procedures. Hospitals and clinics often have established referral networks with primary care physicians, specialists, and other healthcare providers. This facilitates a streamlined referral process for patients with chronic pain, ensuring they receive timely and appropriate care. These factors collectively contribute to the growth of this segment.

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the global Chronic Pain Treatment market in 2024, holding the largest market share in terms of value. North America has a substantial population dealing with chronic pain, including conditions like back pain, arthritis, and neuropathic pain. This high prevalence drives the demand for chronic pain treatments. The region boasts advanced healthcare infrastructure, including well-equipped hospitals, clinics, and specialized pain management centers. These facilities provide a wide range of treatment options for chronic pain. North America is a hub for pharmaceutical research and development. Many innovative pain medications and therapies are developed and marketed in the United States and Canada. While regulations surrounding opioid use have tightened, the regulatory framework in North America ensures the safety and efficacy of pain medications and treatments.

The Asia-Pacific market is poised to be the fastest-growing market, offering lucrative growth opportunities for Chronic Pain Treatment players during the forecast period. Factors such as the Asia-Pacific region is experiencing a steady increase in chronic diseases such as diabetes, cancer, and cardiovascular diseases. These conditions often lead to chronic pain, driving demand for pain management solutions. As the population in countries like Japan, China, and South Korea ages, the prevalence of chronic pain conditions associated with aging, such as osteoarthritis and neuropathy, is on the rise. Many Asia-Pacific countries are increasing their healthcare expenditure, leading to improved access to healthcare services and pain management options. Emerging economies within the region, such as India and Southeast Asian countries, present untapped markets for chronic pain treatment providers. As healthcare infrastructure and awareness improve, the market potential in these countries is substantial. Pharmaceutical companies are expanding their presence in the Asia-Pacific region, bringing new pain medications and therapies to the market.

Recent Developments

• In February 2025, Algiax Pharmaceuticals announced promising topline results from its Phase 2a trial of AP-325, a non-opioid small molecule targeting neuropathic pain through GABAA signaling activation. The study demonstrated AP-325's potential for rapid and sustained pain reduction, offering a breakthrough approach to chronic neuropathic pain management. CEO Dr. Ingo Lehrke emphasized the significance of these findings in providing a well-tolerated, non-addictive treatment option. Algiax Pharmaceuticals is now evaluating the next steps to accelerate AP-325’s availability and improve patient outcomes globally.
• In January 2025, Tris Pharma announced positive topline results from its ALLEVIATE-1 Phase 3 trial evaluating cebranopadol for moderate-to-severe acute pain following abdominoplasty surgery. The investigational therapy, a first-in-class dual-NMR agonist, targets both the nociceptin/orphanin FQ peptide (NOP) and µ-opioid peptide (MOP) receptors. These results reinforce cebranopadol’s potential to provide effective pain relief comparable to opioids while reducing the risk of severe side effects, dependence, and addiction by leveraging the body's natural pain modulation mechanisms.
• In December 2024, Nervonik, a medical device startup specializing in peripheral nerve stimulation (PNS) for chronic pain treatment, has successfully completed its first-in-human clinical study. The study, conducted at Punta Pacifica Hospital in Panama City, tested Nervonik’s proprietary PNS device, originally developed at UCLA. The device uses miniaturized implantable pulse generators, wirelessly powered and customized via a dedicated app for optimal pain relief.
• In October 2024, ANANDA Scientific Inc. announced the launch of a clinical trial to assess Nantheia ATL5, an investigational cannabidiol (CBD) drug with proprietary delivery technology, co-administered with THC, for treating opioid use disorder (OUD) and chronic pain. Conducted at Yale School of Medicine under Principal Investigator Dr. Joao P. De Aquino, the study is funded by the National Institute on Drug Abuse (NIDA). The trial aims to evaluate the drug’s effectiveness in alleviating pain and cue-induced cravings in OUD patients while also assessing whether THC independently influences CBD’s therapeutic effects.

Key Market Players

• Pfizer Inc
• Abbott Laboratories
• Eli Lilly and Company
• Novartis AG
• Johnson & Johnson
• Sanofi SA
• Teva Pharmaceutical Industries Ltd
• Baxter International
• Merck & Co. Inc
• Boston Scientific Corporation

 Report Scope:

In this report, the Global Chronic Pain Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Chronic Pain Treatment Market, By Indication:

o   Neuropathic Pain

o   Analgesic Infusion

o   Ablation

• Chronic Pain Treatment Market, By Product Type:

o   Drugs

o   Devices

• Chronic Pain Treatment Market, By Distribution Channel:

o   Hospital & Clinics

o   Ambulatory Centers

o   Others

• Chronic Pain Treatment Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Pain Treatment Market.

Available Customizations:

Global Chronic Pain Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Chronic Pain Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]